HPRA outlines regulatory priorities for 2026–2029

Ireland’s Health Products Regulatory Authority (HPRA) has published its Strategic Plan 2026–2029, setting out four priorities for adapting regulatory oversight to scientific advances, evolving European legislation and challenges affecting the availability of health products. The strategy focuses on regulatory development, digital transformation, stakeholder cooperation and organisational capability.

Published as the HPRA marks 30 years since its establishment as an independent body and National Competent Authority, the plan describes how the HPRA intends to strengthen its contribution to the Irish, European and international regulatory systems.

Four strategic priorities

The strategy is structured around four goals: regulating for the future; digital first, data driven; partnerships, trust and transparency; and people, capability and culture.

The first goal focuses on supporting innovation, contributing to emerging national and EU legislation, strengthening the HPRA’s role in European medicines authorisation and lifecycle management, and improving the monitoring and management of health product availability.

The authority also intends to strengthen national preparedness for public health emergencies and contribute to Ireland’s One Health National Action Plan on antimicrobial resistance (AMR).

Digital transformation and artificial intelligence

Digitalisation is a central element of the 2026–2029 strategy. The HPRA plans to modernise its regulatory systems through increased automation, improved connectivity and more consistent data exchange aligned with EU digital standards.

Another priority is the integration of real-world evidence (RWE) and novel data sources into regulatory processes. The authority intends to strengthen data governance and secure data-sharing infrastructure to support more effective, data-driven decision-making.

The strategy also identifies artificial intelligence (AI) as an area for further development. The HPRA plans to explore the use of AI and advanced data analytics across its business and regulatory activities, particularly to improve internal analytical and decision-support capabilities.

In parallel, the authority intends to contribute to the development of standards and guidance on the application of AI technologies to health product regulation.

Stronger role in European regulatory cooperation

The HPRA intends to reinforce its participation in the European regulatory network and contribute to the development of national, EU and international regulatory frameworks.

One of the stated outcomes is a net increase in the portfolio of medicines authorised in Ireland during the strategy period, alongside a stronger contribution to European regulatory capacity and the lifecycle management of health products.

The authority also plans to strengthen cooperation with healthcare stakeholders, patients and other regulatory bodies. This includes further development of the HPRA Patient Forum and support for the delivery of Ireland’s Presidency of the Council of the European Union.

Organisational capability and sustainability

The fourth goal addresses the expertise and resources needed to deliver the authority’s regulatory responsibilities. Planned measures include targeted professional development, digital and data skills training, succession planning and organisational adjustments in response to changes in the regulatory environment.

The strategy also covers long-term financial, environmental and infrastructure sustainability, as well as equality, inclusion and human rights across the organisation.

A framework for the next four years

The Strategic Plan 2026–2029 provides the HPRA with a framework for adapting its regulatory activities to changes in science, technology and European legislation.

Its priorities combine the development of regulatory science, greater use of digital technologies and data, stronger European cooperation and measures to support the availability of health products. The document sets out the authority’s intended direction for the four-year period rather than introducing new regulatory requirements for industry.

Read the HPRA Strategic Plan 2026–2029 and access the official document in the TOP-Pharma Resource Center: TP-DOC-012.

📄

HPRA Strategic Plan 2026–2029

Access the official document in the TOP-Pharma Resource Centre.

POPULAR